Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azilsartan for coronary microcirculation dysfunction after PCI
ChiCTR2300071431Phase 4Not yet recruiting
- Sponsor
- Shaanxi Provincial People’s Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of azilsartan in coronary arteriosclerosis and Coronary Small Vessel Disease (CMD) (2 arms), sponsored by Shaanxi Provincial People’s Hospital. Primary endpoints: Coronary flow reserve fraction, SIRT1 and 2 more. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
azilsartan
03
Conditions
coronary arteriosclerosisCoronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on ChiCTR2300071431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071431.